Audited Financial Results for the Quarter and Financial Year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Everest Organics reported a sharp deterioration in FY25 results. Total income fell to Rs. 16,016.59 lakhs from Rs. 19,412.74 lakhs in FY24, a decline of around 17%. The company swung to a net loss of Rs. 129.03 lakhs for the year, compared to a profit of Rs. 291.30 lakhs in the previous year, translating to a loss per share of Rs. 2.97. Operating cash flow also turned negative at minus Rs. 537.69 lakhs against positive Rs. 1,607.32 lakhs last year. The statutory auditors issued a qualified opinion, flagging that the company is producing beyond approved TSPCB capacity limits without the required consents, a recurring qualification for four years that could affect its going concern status. The company raised Rs. 2,700 lakhs through a preferential share issue and warrants during Q4 to fund a new production block and working capital needs.
Shareholders should note the swing to losses, shrinking top line, and a qualified audit report with a going concern caveat — all of which are negative signals for the stock. The fresh equity dilution from the preferential issue will also reduce per-share value for existing holders.